IMPORTANCE Surgical resection has a potential benefit for patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction.
G astric cancer is often diagnosed in locally advanced or metastatic stage and, therefore, has a poor prognosis. Systemic chemotherapy is recommended for patients with stage II or III disease as neoadjuvant or perioperative treatment and for patients with stage IV as a singlemodality treatment. In the latter case, only 10% of the patients survive longer than 2 years. Unlike with other tumor entities, such as colon and ovarian cancer, in which multimodality approaches are frequently used for select patients in stage IV, patients with metastatic gastric cancer generally receive only palliative chemotherapy.
A number of retrospective analyses examined the role of surgery of the primary tumor and/or metastases for patients with stage IV gastric cancer and suggested that surgery might be associated with prolonged survival in select patients, such as those 70 years or younger who had 1 metastatic site, 1 those with 1 incurable site and excellent response to systemic preoperative chemotherapy, 2,3 and those with liver metastases in whom complete resection was possible. 4 However, the role of surgical intervention for metastatic gastric cancer remains an open question. A recent trial in Asia (REGATTA) randomized 175 patients with gastric cancer and a single noncurable site to chemotherapy alone or to initial gastrectomy (without resection of the metastases) followed by chemotherapy. That trial failed to show improvements in survival.
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In the debate on how to conduct further studies in this field, we consider 3 theoretical aspects to be important: (1) the proper selection of suitable candidates for surgery, (2) the clear definition of the goal of the surgery (eg, palliative or curative), and (3) the necessity to administer effective systemic chemotherapy prior to surgery.
Here, we report on the feasibility and efficacy of using induction chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) followed by surgical resection with curative or life-prolonging intent for select patients with limited metastatic gastric cancer. We chose FLOT treatment because of its confirmed tolerability 6,7 and ability to induce considerable rates (up to 20%) of complete pathological regression.
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Methods
Patient Eligibility
Patients with histologically confirmed, previously untreated, nonmetastatic, operable (>T2, N any, and M0 or any T, N+, and M0) or metastatic (T any, N any, and M1) adenocarcinoma of the stomach or esophagogastric junction were eligible to participate in this AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial (NCT00849615). Patients with recurrent disease were not. An Eastern Cooperative Oncology Group performance status of 0 to 2, sufficient bone marrow and kidney function, and no concurrent, uncontrolled medical illness were required of trial participants. The protocol (available in Supplement 1) and the patient informed consent form were approved by the ethics committees of all participating cancer care centers (eAppendix 1 in Supplement 2). Participants provided written informed consent.
Clinical Staging and Group Stratification
Patients underwent preoperative staging that consisted of endoscopy, endoscopic ultrasonography, and computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis. Patients who were potentially resectable or had limited metastases were recommended to undergo diagnostic laparoscopy. In case of suspected bone lesions on CT scans, additional bone scans were required. After pretreatment staging, patients were stratified by the investigator into 1 of 3 groups-resectable (arm A), limited metastatic (arm B), or extensive metastatic (arm C)-using the following criteria:
• Arm A, resectable tumors without distant metastases (cM0).
• Arm B, metastatic tumors (cM1) with all of the following criteria fulfilled:
• abdominal, retroperitoneal lymph node metastases only (eg, para-aortic, intra-aortic-caval, peripancreatic, or mesenterial lymph nodes) or 1 incurable organ site with or without retroperitoneal lymph node metastases; • no clinically visible (on CT scans or because of ascites) or symptomatic carcinomatosis of peritoneum or pleura and no diffuse (>P2 score; eAppendix 2 in Supplement 2) peritoneal carcinomatosis on diagnostic laparoscopy; • fewer than 5 liver metastases, if the single organ site is the liver; • Eastern Cooperative Oncology Group performance status of 0or1;and • normal serum alkaline phosphatase levels.
• Furthermore, the following specific cases were predefined in the study protocol: localized peritoneal carcinomatosis (P1 or P2 score), according to the classification of the Japanese Research Society for Gastric Cancer, was allowed and considered 1 incurable organ site. Bilateral or unilateral Krukenberg tumors were allowed and considered 1 incurable organ site. Unilateral or bilateral adrenal gland metastases were also considered 1 incurable organ site. Extraabdominal lymph node metastases, such as supraclavicular lymph node involvement, were allowed and considered 1 incurable organ site.
Key Points
Question Is there a survival benefit for patients with limited metastatic gastric or gastroesophageal junction cancer who receive neoadjuvant chemotherapy followed by surgical resection?
Findings In this phase 2 trial that enrolled 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma, 60 of the 238 eligible patients were classified as having limited metastatic stage and 36 of these 60 patients had surgery, including resection of the primary tumor and metastases. The median overall survival was 31.3 months for patients who underwent surgery and 15.9 months for the other patients.
Meaning
Patients with limited metastatic gastric or gastroesophageal junction cancer may benefit from neoadjuvant chemotherapy followed by surgical resection.
• Arm C, metastatic patients who did not fulfill the criteria of arm B.
Retroperitoneal lymph node involvement was defined as an abnormally increased number of retroperitoneal lymph nodes measuring more than 1 cm in the short-axis diameter or a single lymph node measuring more than 2 cm in the short-axis diameter. The stratification was confirmed by central review (S.-E.A.-B.). If necessary, central review requested additional information and documents or contacted the investigator to achieve consensus.
Treatment Plan
The . Each is an intravenous infusion followed by fluorouracil, 2600 mg/m 2 , as a 24-hour continuous intravenous infusion on day 1, repeated every 2 weeks. 6 (FLOT is a 2-week regimen.)
Patients in arm A received 4 cycles of preoperative FLOT followed by surgery and 4 postoperative cycles. Patients in arm B received 4 cycles of FLOT and proceeded to surgery if restaging showed a realistic chance for margin-free (R0) resection of the primary tumor and at least a "macroscopic complete resection" of the metastatic lesions. For final decision, we took into consideration the current patient's Eastern Cooperative Oncology Group performance status, comorbidity, organ function, and response to FLOT treatment. After surgery, patients in arm B received 4 additional postoperative cycles of FLOT (8 cycles in total). Patients who did not proceed to surgery after the fourth cycle continued to receive 4 additional cycles (8 cycles in total). Patients in arm C received 8 cycles, and surgical interventions were allowed for palliative reasons. In treatment arms B and C, the maximum duration of FLOT treatment could be extended to a maximum of 12 cycles at the investigator's discretion.
Surgery
Restaging through CT or MRI scans and endoscopy of the upper gastrointestinal tract was repeated after 4 cycles prior to surgical treatment, which was 3 weeks after the last cycle of preoperative chemotherapy. Surgery was performed according to German standards: the AIO-FLOT3 trial protocol suggested transthoracic esophagectomy with resection of the proximal stomach (Ivor-Lewis procedure) and 2-field lymphadenectomy for type I gastroesophageal junction cancers and gastrectomy with transhiatal distal esophagectomy plus D2 lymphadenectomy for types II and III gastroesophageal junction cancers. For gastric cancer, total or subtotal distal gastrectomy with D2 lymphadenectomy was recommended. The study protocol provided recommendations on surgical intervention for these specific situations in arm B: para-aortic involvement, peripheral or central liver metastases, localized peritoneal carcinomatosis, and metastases to adrenal glands (eAppendix 2 in Supplement 2).
Toxicity Assessment
Toxic effects were graded according to the National Cancer Institute's Common Toxicity Criteria, version 3.0.
11 Postoperative morbidity and mortality were recorded.
Evaluation of Efficacy Outcomes
Response in the metastatic groups (arms B and C) was classified according to RECIST (Response Evaluation Criteria in Solid Tumors), version 1.0. 12 Tumor assessment through CT or MRI scans was carried out every 8 weeks during and after the end of the study treatment (for patients who discontinued the study without disease progression). R0 resection was defined as no tumor identified on microscopic examination of proximal, distal, or circumferential margins.
End Points and Statistical Analysis
We assumed that if patients in arm B (independent of whether patients had an operation) showed a better outcome than did patients in arm C, we could justify the further evaluation of neoadjuvant chemotherapy followed by surgical resection in the patient group of arm B. Therefore, the primary end point was overall survival (OS), and the study had 80% power to detect a 45% 
Results

Patient Characteristics
Between February 1, 2009, and January 31, 2010, we enrolled 252 patients (and stratified them to arm A, 52; arm B, 67; and arm C, 133) in 52 centers in Germany (eAppendix 1 in Supplement 2). Of the 252 patients, 14 (5.6%) were excluded from the efficacy analysis for these reasons: 10 had recurrent disease, 2 had ineligible underlying disease (ie, breast cancer, hepatocellular carcinoma), 1 had received prior chemotherapy, and 1 was stratified into arm B but was confirmed having M0 disease at on-site monitoring. Therefore, 238 patients (94.4%) were eligible for the efficacy analysis (arm A, 51 patients; arm B, 60; arm C, 127). Details are shown in Figure 1 . 
Chemotherapy and Surgical Treatment
Patients received a median (range) of 8 (1-15) cycles of FLOT. The median (range) numbers of preoperative and postoperative cycles were 4 (preoperative, 3-15; postoperative, 1-7) for each arms of A and B. Forty-nine patients (96.1%) in arm A, 36 (60%) in arm B, and 15 (11.8%) in arm C proceeded to any surgical resection. R0 resections of the primary tumor were achieved in 40 patients (81.6%) in arm A, 29 (80.6%) in arm B, and 5 (33.3%) in arm C. As shown in eTable 2 in Supplement 2, fewer patients in arm B than in arm A had a right transthoracic esophagectomy with 2-field lymph node dissection despite the fact that junctional tumors were more frequent in arm B.
In arm B, surgery was performed in 18 of 27 patients (66.7%) with retroperitoneal lymph node metastases, 6 of 11 (54.5%) with liver metastases, 6 of 10 (60%) with lung metastases, 2 of 4 (50%) with local peritoneal carcinomatosis, and 4 of 8 (50%) with other metastases. Metastasectomy of at least 1 metastatic lesion was performed in 17 of the 36 patients (47.2%) who were assigned to surgery in arm B. These surgical procedures included D3 lymphadenectomy in 7 patients, peritonectomy in 3, multivisceral resections in 3, hepatectomy in 3, and adrenalectomy in 1. Among the 18 patients with retroperitoneal lymph node metastases who underwent a resection, metastatic lymph node involvement could be confirmed in 11 patients but was not assessable in 3 patients who had complete pathological regression and could not be confirmed in the other 4 patients. Complete pathological regression (stage of T0) was reported in 6 of 36 patients (16.7%) of arm B who underwent resection. Complete regression in resected metastatic lesions, as indicated by fibrotic changes and the absence of malignant cells, was noticed in 3 patients (retroperitoneal lymph nodes in 2 patients and liver lesions in 1 patient). The reasons for not assigning patients to surgery in arm B were unresectable or incurable metastatic lesions in 11 of 60 patients (18.3%), inadequate response in 6 (10%), death in 2 (3.3%), complete response in 1 (1.7%), medical inoperability in 1 (1.7%), patient refusal in 1 (1.7%), and unknown in 2 (3.3%), as reported by the investigator.
Efficacy Outcomes
Median follow-up for surviving patients was 28.6 months (arm A, 30.3 months; arm B, 27.5 months; arm C, 24.4 months). Median OS was 22.9 (95% CI, 16.5-upper level not achieved) months in arm B and 10.7 (95% CI, 9.1-12.8) months in arm C (HR, 0.37; 95% CI, 0.25-0.55; P < .001). Median OS in arm A was not achieved and compared favorably with the median OS in arm B. The analysis of progression-free survival among the arms revealed distributions similar to OS distributions ( Figure 2 ). Table 1 .Among the subgroups of arm B, only patients with retroperitoneal lymph node metastases had the best prognosis, whereas patients with liver metastases showed a less favorable survival (eFigure in Supplement 2). The overall response rate (complete and partial response) to chemotherapy was higher in arm B patients than in arm C patients (60.0% vs 43.3%; P = .04). Response rates are shown in Table 2 .
We compared the baseline characteristics and comorbidities of patients who proceeded to surgery with those who did not within arm B. No differences in age, sex, location of the primary tumor, histological type, type of metastases, and other characteristics were found. However, patients who did not undergo surgery had significantly more active comorbidities than patients who had surgery (20 of 
Safety
The safety analysis comprised all 252 patients. The safety profile of FLOT was in line with the profile of previous studies.
6,7,10,13 Patients in arm C had significantly more Common Toxicity Criteria all-grades anemia, pain, and elevated alkaline phosphatase levels, most likely correlated with the high tumor burden (eTable 3 in Supplement 2). Severe postsurgical morbidity (fulfilling the criteria of a serious adverse event) affected 5 patients (10.2%) in arm A and 3 patients (8.3%) in arm B (eTable 4 in Supplement 2). Numbers do not represent the overall postsurgical morbidity because only those that re- sulted in serious adverse events are reported. In-hospital mortality after surgery occurred in 1 patient in arm A.
Discussion
The AIO-FLOT3 trial was an exploratory, phase 2 study that prospectively evaluated the feasibility and efficacy of induction chemotherapy followed by surgery for patients with limited metastatic gastric cancer who had additional favorable prognostic factors. Sixty patients had limited metastatic disease (arm B), and they had a considerable median OS of 22.9 months. Of the 60 patients, 36 (60%) proceeded to surgery. The median OS was 31.3 months for patients who underwent surgery and 15.9 months for the other patients. Both groups had survival rates that were markedly better than the expected survival for metastatic disease, which were generally accepted to be 9 to 11 months in recent trials. The important question is to what extent surgery contributed to the favorable outcome of the resected group. Because of the lack of randomization, relevant selection bias may exist. For instance, a difference in comorbidity was observed between the groups. Patients assigned to surgery had less active comorbidity than the patients who did not have surgery (50.0% vs 83.3%). The most common reason for not assigning patients to surgery was the investigator's decision that metastatic lesions were unresectable or incurable after neoadjuvant chemotherapy. Conversely, this means that patients assigned to surgery were superselected. Nevertheless, within these limitations, the considerable survival in the surgical group of arm B remains promising. A median survival of 31 months is more than we would expect in a superselected group of patients with metastatic disease. Patients with retroperitoneal lymph node metastases or liver metastases represented the 2 largest subgroups of arm B. Patients with retroperitoneal lymph node metastases showed the best survival. This patient group may be of a particular interest for such a bimodality therapy approach.
14-18 One important point is whether CT or MRI was sufficient to determine retroperitoneal involvement. The accuracy of CT or MRI for defining lymph node involvement is dependent on the anatomical location. In the abdomen, the upper limit of the short-axis diameter of normal nodes varies from 6 to 10 mm. 19 The study protocol went beyond these definitions, requiring either too many lymph nodes (lymph node clusters) greater than 1 cm in the short axis or single lymph nodes greater than 2 cm. Therefore, we do not believe that arm B was inflated by patients with nonmetastatic lymphatic hyperplasia. The less favorable outcome of patients with liver metastases leads us to recommend to either exclude this group in future trials or limit the group to patients in whom complete (R0) resection is judged possible at initial evaluation. Nevertheless, few patients with metastatic gastric cancer will have initially resectable liver disease.
4,20
The REGATTA trial 5 randomized 175 patients with gastric cancer and a single noncurable site confined to liver, peritoneum, or para-aortic lymph nodes to chemotherapy alone or gastrectomy followed by chemotherapy. The study did not show any improvement of OS by gastrectomy (median OS, 16.6 months without gastrectomy and 14.3 months with gastrectomy). 5 The concept of the REGATTA trial differs from the concept of the AIO-FLOT3 trial in 2 important ways. First, patients in the REGATTA trial did not receive neoadjuvant chemotherapy. Second, the surgical intervention was restricted to only gastrectomy with D1 lymphadenectomy without any resection of metastatic lesions, making the study palliative rather than curative. As mentioned in the Introduction, we believe the use of neoadjuvant therapy and the pursuit of a potentially curative surgery are 2 crucial factors in a multimodality approach to a biologically aggressive disease such as metastatic gastric cancer. Administering chemotherapy first Tumor assessments performed after surgery were not relevant for response.
b P = .04 for the numbers of patients with overall response (complete + partial) in arm B compared with those in arm C, using 2-sided Fisher exact test. The P value is presented only if P < .05.
Research Original Investigation
helps prevent a delay in administration of the systemic treatment component, which has been proven to be effective. Moreover, administering chemotherapy first provides a tool for selecting patients with the highest likelihood to benefit from additional surgery, on the basis of their response to treatment and other factors.
Limitations
The main limitation of the AIO-FLOT3 trial was the lack of randomization. Another limitation was the use of CT or MRI to determine retroperitoneal involvement. Both of these topics were addressed in the discussion.
Conclusions
To our knowledge, the AIO-FLOT3 trial is the first prospective study to evaluate neoadjuvant chemotherapy followed by surgery in patients with metastatic gastric and gastroesophageal junction cancer. Within the limitations of a nonrandomized phase 2 study, the results reported here showed that the concept was feasible and provided a rationale for an ongoing, randomized Handling potentially operable patients (summary of chapter 13.1 and 13.2. of the study protocol): Patients should be offered a comprehensive nutritional consultation directly after the surgery and 2 months later.
Stratum B
In patients with limited metastatic disease in whom surgical resection is pursued, investigators will Clinical examinations (blood count, assessment of toxicity, anamnesis) are performed every two weeks for evaluation of toxicity and application of chemotherapy. After informed consent is given, 2 ml of peripheral blood of the patient will be analysed for the pharmacogenetic risk profile.
Representative tumor material (formalin-fixed and paraffin-embedded) will be analysed within translational projects. In adenocarcinomas of the lower esophagus, affected coeliac lymphnodes are defined as M1 situation. Patients with relapse (local or systemic) after curative resection are not eligible for this study. Patients with synchronous metastases (M1) who had surgery due to imminent complications (e.g. bleeding or occlusion) or whose metastasis was previously unknown are eligible for the study under the condition that not all measurable lesions were removed. Resected metastases will be included in classification of affected organs for stratification (Stratum B v C).
Inclusion Criteria
Exclusion Criteria
1. Known hypersensitivity against 5-Fluorouracil, Leucovorin, Oxaliplatin or Docetaxel 2. Other known contraindications against 5-Fluorouracil, Leucovorin, Oxaliplatin or Docetaxel 3. Active coronary heart disease, cardiomyopathy or congestive heart failure, NYHA III-IV 4. Malignant secondary disease, dated back < 5 years (exception: In-situ-carcinoma of the cervix uteri, adequately treated skin basal cell carcinoma) 5. Brain metastases (AST/ALT>3,5xULN, AP>6xULN, Bilirubin>1,5xULN) 9. Chronic inflammable gastro-intestinal disease 10. inclusion in another clinical trial 11. pregnancy or lactation
Stratification
Stratum A, resectable tumors without distant metastases (cM0).
Stratum B, metastatic tumors with all of the following criteria fulfilled:
-abdominal, retroperitoneal lymph node metastases only (e.g. para-aortal, intra-aortocaval, peripancreatic or mesenterial lymph nodes) or a single organ site involved with or without retroperitoneal lymph node metastases. -no clinically (on CT scans or because of ascites) visible or symptomatic carcinomatosis of peritoneum or pleura and no diffuse peritoneal carcinomatosis on diagnostic laparoscopy. -less than 5 liver metastases, if the single organ site is the liver.
-ECOG performance status of 0 or 1.
-serum alkaline phosphatase within normal ranges.
-furthermore, the following specific cases are pre-defined in the protocol: localized peritoneal carcinomatosis (P1 or P2) according to the classification of the Japanese Research Society for Gastric Cancer [Japanese Gastric Cancer Association 1998] is allowed and considered a single organ site. Bi-or unilateral Krukenberg tumors are allowed and are considered a single organ site. Uni-or bilateral adrenal gland metastases are also considered a single organ site. Extra-abdominal lymph node metastases such as supraclavicular lymph node involvement are allowed and are considered a single organ site.
Stratum C, metastatic patients who do not fulfill the criteria of Arm B.
Sample Size
Patients
Statistics Sample Size Calculation (Chapter 7 of the protocol)
In this study, the prospective influence of localization and extent of metastases on overall survival of patients with advanced gastric cancer will be evaluated. Metastatic stage will be assessed by predefined criteria and patients are allocated to stratum B (limited metastatic) and stratum C (extensive metastatic). Expected ratio of B:C is calculated as 1:2. In addition, a stratum A is included into the study consisting of patients with localized, operable tumors. This group is not considered for the primary hypothesis but is a control group for relativation of results in group B and C within identical study conditions.
Based on previous analyses, the following assumptions for sample size calculation are derived. For stratum C, a median survival of 8 months is expected, and approximately the double time is estimated a reasonable and clinically relevant goal for stratum B (Hazard Ratio 0.55). The hypothesis will be tested one-sided with an alpha error (error of 1st kind) of 2.5%. Assuming a power of 80%, a total of 192 patients in strata B and C have to be included (nB = 64, nC = 128).
Endpoints
Primary endpoint for efficacy of the therapy is overall survival defined as time from on-study date until death. Quality of life will be evaluated by the questionnaires EORTC-QLQ C30, STO22 and LQMN1 at baseline and then every two months, if possible also after progression of disease.
Progression-free survival (PFS) is defined as time from start of therapy (on-study date) until progression of disease or death of the patient. Safety will be analysed by number, severity and duration of adverse events (with causal relationship to study medication) of all patients who received at least one dose of combination therapy. Adverse events will be reported descriptively by tabulation including CTC grade (CTC-AE version 3). Additionally, serious adverse events will be presented individually with details on severity, duration and outcome of the event (Simon et al. 1997).
In this study, the validation of a pharmacogenetic risk profile for patients with advanced gastric cancer with first-line chemotherapy is planned. Risk parameters were defined in the context of previous clinical studies of our group. Confirmation of a difference of 2.7 months in PFS between a "high-risk" group (HR, PFS 4 months) and a "low-risk" group (HR, PFS 6.7 months) is intended by use of a prospectively defined risk profile. For these analyses, with a hazard ratio of maximal 0.55 and power of 80%, with one-sided significance of 2.5%, a sample size of 100 patients per group is necessary. It can be expected that for a per protocol analysis the planned study population is sufficient for analysis of this endpoint. Allocation to high-or low-risk group will be based on a combined analysis of two genetic polymorphisms of the metabolism of the study substances (XPD312 and MTR2756).
Statistical plan
General parameters: First patient in Last patient in Definition of Population Total Population (all patients), no. of patients in the three strata (A, B, C). Eligible Population: total population minus patients excluded due to major violation of inclusion criteria; no. of patients in the three strata (A, B, C) Safety Population: Patients who received at least one dose of FLOT. Listing of patients excluded from the total population, description of reasons
All following parameters should be analysed in the total population and the eligible population Baseline Criteria (i.e. demographic data, patient´s characteristics etc.), compared in the three strata (p-values for differences) Duration of therapy (days), no. of cycles (median, range), compared in the 3 strata (optional, cumulative doses etc.)
No. of patients with: 0-4, 5-8, 9-12, >12 cycles in all 3 strata Reasons for therapy discontinuation in all 3 strata Interruption and dose modification in all 3 strata Median Follow-up (+ range) in the total population (months) Distant lymph node metastases only For patients with lymph node involvement classified as distant metastases (e.g. paraaortal, paracaval or mesenterial lymph nodes), metastases should be resected within the first intervention in the framework of an extended lymphadenectomy (one-stage resection). Postoperative external radiation may be considered upon investigator´s decision and should be sequential but not simultaneous with postoperative FLOT therapy.
Peripheral liver metastases
Patients with singular, peripheral liver metastases. Investigators can handle resectable liver lesions similar to colon cancer. Peripheral liver lesions may be resected within the primary intervention (one-stage resection).
Adrenal metastases
Patients with singular adrenal metastases. Adrenal metastases will be completely resected within the primary intervention (one-stage resection).
Limited peritoneal metastases
Classification of peritoneal metastases for this protocol will be conducted in accordance with the "P-Score of the Japanese Research Society for Gastric Cancer" (see Table below ). P1 and P2 are classified as limited metastases. P3 or clinical detectable diffuse affection of peritoneum like e.g. large quantities of ascites are classified as diffuse peritoneal carcinomatosis and thus as diffuse metastasis (Stratum C). Table: P-Score according to "Japanese Research Society for Gastric Cancer"
P 0
No disseminating metastases to the gastric serosa, greater or lesser omentum, mesenterium, visceral and parietal peritoneum and retroperitoneum
P 1
Disseminating metastasis to the adjacent peritoneum (above the transverse colon and including the greater omentum) without metastasis to the distant peritoneum, i.e. the peritoneum below the transverse colon and the abdominal surface of the
P 2
A few to several scattered metastases to the distant peritoneum, e.g. only ovarian metastases (Krukenberg)
P 3
Numerous metastases to the distant peritoneum Parietal and visceral peritonectomy should be performed in patients with limited peritoneal carcinomatosis if surgery is indicated. Single intraoperative or intra-peritoneal chemotherapy (Cisplatin) is allowed, if in accordance with center-specific standards. Surgery of the primary tumor shall be performed according to the above stated descriptions in primary operable patients. The aim of surgery in Stratum B is R0 resection regarding primary tumor and complete macroscopic cytoreduction regarding resected metastases.
Central liver metastases
In general, investigators can handle central liver lesions similar to colon cancer. If indication for surgery was given, a two-stage resection may be considered. In this case, chemotherapy cycles should be interposed in order to avoid a tumor progress between resections.
*Other: Arm B: adrenal gland (1), pericardial involvment (1); Arm C: adrenal gland (4), colon (2), abdominal wall/omentum majus (1), bone marrow (1), kidney (1), muscle (1), pancreas (1), pleuracarcinosis (1), uterus (1). 
